Skip to main content

Table 1 The association between histological findings and methylation analysis with and without hrHPV testing

From: DNA methylation for cervical cancer screening: a training set in China

HistologyPositiveaEPB41L3, n (%)PositiveaJAM3, n (%)Positive EPB41L3 or positive JAM3, n (%)Positive hrHPV, n (%)Positive hrHPV + methylation, n (%)
Inflammation or LSIL (n = 118)Inflammation (n = 78)4 (5.13)7 (8.97)8 (10.26)55 (70.51)5 (9.09)
CIN1 (n = 40)1 (2.50)1 (2.50)2 (5.00)31 (77.50)1 (3.23)
HSIL (n = 120)CIN2 (n = 29)3 (10.34)5 (17.24)6 (20.69)21 (72.41)4 (19.05)
CIN3 (n = 91)56 (61.54)64 (70.33)65 (71.43)83 (91.21)61 (73.49)
Malignancies (n = 68)SCC (n = 52)51 (98.08)51 (98.08)51 (98.08)49 (94.23)49 (94.23)
Endocervical ADC (n = 11)8 (72.73)10 (90.91)10 (90.91)9 (81.82)9 (81.82)
  1. ADC adenocarcinoma, CIN cervical intraepithelial neoplasia, HGSC high-grade serous carcinoma, hrHPV high-risk human papilloma virus, SSC squamous cell carcinoma
  2. aPositive methylation status indicates calculated values below the cutoff values